Rapport Therapeutics Soars 143% in Premarket Trading After Positive Phase 2a Trial Results

Shares of Rapport Therapeutics (NASDAQ: RAPP) experienced a dramatic surge of over 143% in premarket trading on September 8, 2025, driven by overwhelmingly positive results from its Phase 2a clinical trial of RAP-219. This groundbreaking treatment for drug-resistant focal onset seizures delivered impressive efficacy metrics, positioning the company to advance into Phase 3 trials and potentially offer hope to patients suffering from epilepsy who haven’t found success with existing treatments.